Literature DB >> 21553639

Generating sociability to drive science: patient advocacy organizations and genetics research.

Aaron Panofsky1.   

Abstract

This paper examines how patient advocacy organizations (PAOs) representing those with rare genetic disorders drive research to their concerns. The rarity of the diseases produces a basic condition of marginalization: small numbers of widely distributed disease sufferers. The lack of promise of an eventual market makes it difficult to attract the economic and biological resources necessary for sustained research. My analysis relies mainly on 21 interviews with leaders from nine PAOs and scientists involved with them, and seeks to understand how PAOs try to attract and influence scientific research. Using a comparative framework, I find that the five main mechanisms emphasized in the literature--economic resources, social movement-style mobilization, moving early, lay expertise, and organizational controls--cannot fully explain the differences in strategies and relationships among members of my PAO sample. I propose instead to show how 'sociability'--forging close relationships with scientists and orchestrating relationships among them--enables PAOs to drive research to their concerns. I show how the strategic manipulation of sociability can give PAOs substantial influence over the research process. However, the forms of sociability that yield the greatest effects are difficult to achieve, and most forms of relationship-building offer PAOs much less influence on research.

Entities:  

Mesh:

Year:  2011        PMID: 21553639     DOI: 10.1177/0306312710385852

Source DB:  PubMed          Journal:  Soc Stud Sci        ISSN: 0306-3127            Impact factor:   3.885


  19 in total

1.  Exploring the positions of German and Israeli patient organizations in the bioethical context of end-of-life policies.

Authors:  Aviad Raz; Isabella Jordan; Silke Schicktanz
Journal:  Health Care Anal       Date:  2014-06

2.  Examining Physician Interactions with Disease Advocacy Organizations.

Authors:  Caroline Horrow; Joel E Pacyna; Carol Cosenza; Richard R Sharp
Journal:  AJOB Empir Bioeth       Date:  2019-08-26

3.  Understanding collective agency in bioethics.

Authors:  Katharina Beier; Isabella Jordan; Claudia Wiesemann; Silke Schicktanz
Journal:  Med Health Care Philos       Date:  2016-09

Review 4.  The role of brain tumor advocacy groups.

Authors:  Michele Rhee; Paulius Mui; Carl Cadogan; Jonny Imerman; Sarah Lindsell; Lainey Titus Samant
Journal:  Curr Neurol Neurosci Rep       Date:  2014-04       Impact factor: 5.081

5.  The "technoscientization" of medicine and its limits: technoscientific identities, biosocialities, and rare disease patient organizations.

Authors:  Peter Wehling
Journal:  Poiesis Prax       Date:  2011-11-10

Review 6.  The involvement of rare disease patient organisations in therapeutic innovation across rare paediatric neurological conditions: a narrative review.

Authors:  Christina Q Nguyen; Kristine Alba-Concepcion; Elizabeth E Palmer; Jackie L Scully; Nicole Millis; Michelle A Farrar
Journal:  Orphanet J Rare Dis       Date:  2022-04-18       Impact factor: 4.303

7.  Patient and interest organizations' views on personalized medicine: a qualitative study.

Authors:  Isabelle Budin-Ljøsne; Jennifer R Harris
Journal:  BMC Med Ethics       Date:  2016-05-13       Impact factor: 2.652

Review 8.  Ethical challenges for a new generation of early-phase pediatric gene therapy trials.

Authors:  Alexander A Iyer; Dimah Saade; Diana Bharucha-Goebel; A Reghan Foley; Gilberto 'Mike' Averion; Eduardo Paredes; Steven Gray; Carsten G Bönnemann; Christine Grady; Saskia Hendriks; Annette Rid
Journal:  Genet Med       Date:  2021-07-07       Impact factor: 8.822

9.  From invited to uninvited participation (and back?): rethinking civil society engagement in technology assessment and development.

Authors:  Peter Wehling
Journal:  Poiesis Prax       Date:  2012-11-16

10.  Disentangling public participation in science and biomedicine.

Authors:  Christopher Kelty; Aaron Panofsky
Journal:  Genome Med       Date:  2014-01-31       Impact factor: 11.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.